Washington has finally decided to treat pharmaceutical supply chains as a national security risk, introducing new policies to wean America off foreign drug dependence. This strategy has been focused primarily, though not exclusively, on China. 

The Trump administration recently announced actions that will cut red tape for new drug manufacturing facilities by reforming permitting, reducing regulatory barriers, strengthening oversight of foreign producers, and speeding up approval timelines.